The New Bacterial Threat
.jpg)
For the past decade or more multiple drug resistant strains of bacteria such as methicillin resistant Staphylococcus aureus (MRSA), enterococci and other Gram positive cocci have been highlighted and showcased in the medical and lay press. While the incidence of infections caused by MRSA and other Gram positive cocci has steadily risen, antibacterial drug discovery experts have long known that the greatest disease threat in the future will be from emerging multiple antibiotic resistant strains of Gram negative bacteria including Acinetobacter baumannii, Klebsiella pneumoniae, Serratia marcescens and Pseudomonas aeruginosa.
Last Spring, in an interview that I conducted with Barry Eisenstein, MD, Senior Vice President of Scientific Affairs at Cubist Pharmaceuticals and an antibacterial drug discovery expert, he indicated that there are currently no drugs in development to treat infections caused by antibiotic resistant Gram negative bacteria. He warned that this, coupled with the loss of interest in antibiotic development by large pharmaceutical companies, will cause infections caused by multiple drug resistant Gram negative bacteria to become a serious unmet medical need in the not so distant future. The appearance of an article in the New York Times this past Saturday chronicling the rise of infections caused by antibiotic resistant Gram negative bacterial suggests that the not so distant future may have already arrived! For the record: would newspaper and television reporters please refrain from identifying bacteria as “germs.” It is an anachronistic term which was coined in the 19th century before bacteria and viruses were conclusively identified as the cause of most infectious diseases.
Despite the media hype about antibiotic resistant Gram positive bacteria, a variety of new drugs have been developed to treat infections caused by these bacteria. Interestingly, because of greater public awareness about MRSA infections and improved hospital infection control and surveillance programs, the incidence of disease caused by MRSA and other Gram positive bacteria is finally beginning to wane. Unfortunately, the same is not true for infections caused by antibiotic resistance Gram negative bacteria.
For those of you who may not know, the cell wall architecture of Gram negative bacteria (and a multitude of antibiotic resistance mechanisms) makes it much more difficult and costly to develop new antibiotics to treat Gram negative infections. Consequently, research in this area has been largely ignored for the past 15 years or so. This means that in the future the morbidity and mortality associated with infections caused by antibiotic resistant Gram negative bacteria is certain to rise. With this in mind, persons at the greatest risk of developing these infections include patients in hospitals and long term care facilities and individuals receiving implantable medical devices.
Because most large pharmaceutical companies abandoned antibiotic drug discovery in the mid to late 1990s, it is unlikely that new Gram negative antibiotics will come from the pharmaceutical sector. While there are several small biopharmaceutical start ups working on antibiotics for Gram negative bacteria (KaloBios Pharmaceuticals, Calixa Therapeutics and Novexel) the increasing regulatory scrutiny and rising development costs suggests that these companies may have trouble bringing new antibiotics to market. Sadly, this places the onus of new Gram negative antibiotic discovery squarely on the shoulders of the US government. To that end, as much as it pains me to say this, it will likely take the death of government official or family member before sufficient resources are allocated to address this rapidly growing unmet medical need. Maybe the Obama Administration ought to think about allocating stimulus monies to begin to address the problem!
Until next time...
Good Luck and Good Job Hunting!!!!!!!
.gif)
While I don’t advocate postdoctoral positions for individuals unless they plan on doing bench science for the rest of their lives, postdoctoral training is a fact of life for those interested in pursuing academic careers. To that end, The Scientist.com conducts an annual survey that ranks the 
For the past decade or more, small to mid-sized biotechnology companies had been outsourcing production of their preclinical and clinical protein-based products to Asian contract manufacturing organizations (CMOs). This was because manufacturing and labor costs were lower and product quality was consistent with Western standards and requirements. However, the recent economic down turn coupled with rising prices at Asian CMOs (mainly driven by increasing labor and project management costs) has .jpg)
American competitiveness in engineering, technology and science. Unfortunately, while American competitiveness and innovation in these areas continues to wane, little has been done (except talking) about it! 
As the competition for traditional life sciences jobs continues to intensify, many PhD-trained life scientists are looking for alternate career opportunities. One of the most popular and intriguing options is business—mostly because each of us more than likely knows somebody “who hit it big” by starting a biotechnology or life science-related company. While the entrepreneurial life isn’t for everyone, those intrepid individuals who are willing to give it a shot and possibly be successful ought to be aware of a few basic tools that will make life as an entrepreneur slightly less stressful. To that end, Emma Taylor over at .jpg)
Carl Ichan, the billionaire, activist investor 
My father was an elementary school teacher who eventually became an elementary school principal, a position that he retired from about 15 years ago. As you might imagine, education was an important part of the lives of my three siblings and me. Like my father, three of four of us eventually pursued careers in education: my sister teaches art to high school students in California; my brother is a professor in the Department of Microbiology at the University of Vermont and I have been a science educator for most of my adult life..gif)
The rising cost of healthcare, increasing drug prices and the restrictive nature of the formularies of many insurers and third party payers is forcing a growing number of Americans to rely almost exclusively on generic prescription drugs. The trouble is that most Americans know very little about generic drugs; mainly because big pharma has done its best to minimize the discussion about generics and continues to portray generic manufacturers as less than reputable purveyors of prescription drugs. Because of this, I think that American ought to begin to understand an industry that increasingly will play a major role in the US healthcare system. So here goes:
Earlier this week, an.jpg)
pharmaceutical industry and seemingly getting tougher.
As many of you may recall, in 2001, Sam Waksal, founder and former CEO of the biotechnology company 
According to an 
Mark Senak, social media enthusiast and author of the .jpg)
While ‘women in the workplace’ is no longer a new or novel concept, there are still differences in the way women and men are viewed and treated at work. Lauri Buckley at (3).jpg)
Mary Canady author of the Comprendia Blog recently (1).jpg)
Amy Bishop, a tenure track faculty member of the Biology Department at the University of Alabama-Huntsville .jpg)
Billy Tauzin, a former Congressman and high profile lobbyist, unexpectedly resigned as President of the Pharmaceutical Research and Manufacturers of America, (PhRMA), a pharmaceutical industry lobby and trade organization. According to a .jpg)
Conventional wisdom suggests that getting involved with a work colleague is not the best thing to do. However, given the amount of time that many of us spend out work, sometimes it is difficult not to enter into work place relationship. Speaking from experience, most work place romances don’t end well or have happy endings. That said, for those intrepid souls who have no choice but to follow their hearts, I happened upon an article that may provide some advice to help navigate the often treacherous and troublesome waters of an office romance.
Things are just not going well for Natick, MA-based device manufacturer Boston Scientific. Yesterday, the company announced that it lost $1.1 billion in the fourth quarter this year. The losses mainly stem from the company’s $1.73 billion .jpg)
Preparing for and executing a job search can be both intimidating and overwhelming. While most job seekers approach a job search without much thought or planning, there actually is a “method to the madness” of a job search. And, if you take the time to develop a strategic plan, your likelihood of success increases almost exponentially. 
After announcing that it would 
In previous .jpg)
A rare or orphan disease is defined in the US as one that affects fewer than 200,000 at any given time. It is estimated that there are 6000 to 8000 rare diseases in the world today. Because the number of patients afflicted with orphan diseases is so small, drug companies have historically been reluctant to invest money to discover and develop new treatments for them. The dearth of treatments for rare diseases induced Congress to pass the
It goes without saying that the competition for jobs in the life sciences industry is extremely fierce. This means that job candidates must use whatever means possible to differentiate themselves from the hundreds, perhaps thousands, of others applying for the same job!
.jpg)
I was introduced to single malt Scotch whisky about six years ago after my in-laws returned from a distillery tour of Scotland. Never a scotch drinker, after sampling a variety of brands, I decided that Islay single malts, most notably 
Many people, most notably GlaxoSmithKline employees, assumed that GSK management would disclose at its earning call yesterday how many people would lose their jobs in the company’s next round of job cuts announced earlier this week. Surprisingly, management decided not to announce the breadth and depth of layoffs ostensibly increasing the drama and anxiety of its employees about the cuts..jpg)
The past couple of weeks have been awful for employees at 
There was a very 
Despite the announcement late last week in the London Sunday Times that .jpg)
The loss of over 200,000 pharmaceutical jobs over the past three years has been mainly driven by the anticipated loss of revenue from blockbuster drugs that will lose patent protection by 2013. While drug makers frequently cite blockbuster patent expiry as the reason for the need to downsize, they rarely provide the business and economic metrics, numbers and statistics that have influenced their decisions. 